MX2016016063A - Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. - Google Patents

Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.

Info

Publication number
MX2016016063A
MX2016016063A MX2016016063A MX2016016063A MX2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A MX 2016016063 A MX2016016063 A MX 2016016063A
Authority
MX
Mexico
Prior art keywords
mic
compounds
fusion proteins
relates
terminus
Prior art date
Application number
MX2016016063A
Other languages
English (en)
Inventor
Thøgersen Henning
Vilbour Andersen Kim
HELGSTRAND Charlotte
Paolo Bastner SANDRINI Michael
Beck Jørgensen Sebastian
Sass-Ørum Kristian
Hastrup Sven
Christian Shaw Allan
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2016016063A publication Critical patent/MX2016016063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a proteínas de fusión de MIC-1. De manera más específica, se refiere a compuestos que comprenden proteínas de fusión que comprenden una proteína MIC-1 o un análogo de la misma en el C-terminal-terminal de la proteína de fusión y una variante funcional de la albúmina de suero humano en el N-terminal de la proteína de fusión conectada a través de un enlazador peptídico. Los compuestos de la invención tienen actividad de MIC-1. La invención también se refiere a composiciones farmacéuticas que comprenden esos compuestos y excipientes farmacéuticamente aceptables, así como el uso médico de los compuestos.
MX2016016063A 2014-06-24 2015-06-17 Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. MX2016016063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173664 2014-06-24
PCT/EP2015/063596 WO2015197446A1 (en) 2014-06-24 2015-06-17 Mic-1 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2016016063A true MX2016016063A (es) 2017-03-10

Family

ID=51032955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016063A MX2016016063A (es) 2014-06-24 2015-06-17 Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.

Country Status (15)

Country Link
US (2) US9272019B2 (es)
EP (1) EP3160496B1 (es)
JP (1) JP6696915B2 (es)
KR (1) KR20170020383A (es)
CN (1) CN106459222A (es)
AR (1) AR100945A1 (es)
AU (1) AU2015279525A1 (es)
BR (1) BR112016029848A2 (es)
CA (1) CA2952293A1 (es)
IL (1) IL249327A0 (es)
MX (1) MX2016016063A (es)
RU (1) RU2017101436A (es)
TW (1) TW201613958A (es)
WO (1) WO2015197446A1 (es)
ZA (1) ZA201608214B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EA202092386A1 (ru) 2013-07-31 2021-04-30 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
GB201615844D0 (en) * 2016-09-16 2016-11-02 Genagon Therapeutics Ab Agents for use in therapy
AU2017371382A1 (en) * 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700553D0 (en) * 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
JP2020517657A (ja) * 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
MA50233A (fr) 2017-09-10 2020-07-22 Novo Nordisk As Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
US20230143988A1 (en) 2018-04-09 2023-05-11 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2020031149A2 (en) 2018-08-10 2020-02-13 Novartis Ag Gfral extracellular domains and methods of use
EP4041281A1 (en) 2019-10-04 2022-08-17 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
BR112022011286A2 (pt) * 2019-12-09 2022-09-06 Alexion Pharma Inc Polipeptídeos da fosfatase alcalina e métodos de uso dos mesmos
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
KR102195740B1 (ko) * 2020-03-25 2020-12-28 서울대학교산학협력단 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
WO2021194257A1 (ko) * 2020-03-25 2021-09-30 (주) 업테라 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템
CN115244076B (zh) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
CN112694520B (zh) * 2020-12-02 2023-01-17 图凌(杭州)生物医药有限公司 一种人工多肽hm、其抗体及在病理检测中的应用
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2005113606A2 (en) * 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
AU2005266184A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2807266B1 (en) * 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
EA202092386A1 (ru) 2013-07-31 2021-04-30 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf15)

Also Published As

Publication number Publication date
AU2015279525A1 (en) 2016-12-15
WO2015197446A1 (en) 2015-12-30
US9956264B2 (en) 2018-05-01
JP2017528419A (ja) 2017-09-28
CA2952293A1 (en) 2015-12-30
AR100945A1 (es) 2016-11-09
US9272019B2 (en) 2016-03-01
US20160015784A1 (en) 2016-01-21
RU2017101436A (ru) 2018-07-24
IL249327A0 (en) 2017-02-28
CN106459222A (zh) 2017-02-22
US20160129083A1 (en) 2016-05-12
ZA201608214B (en) 2018-11-28
JP6696915B2 (ja) 2020-05-20
BR112016029848A2 (pt) 2017-10-24
RU2017101436A3 (es) 2019-02-13
KR20170020383A (ko) 2017-02-22
EP3160496A1 (en) 2017-05-03
EP3160496B1 (en) 2021-03-03
TW201613958A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
TW201613958A (en) MIC-1 fusion proteins and uses thereof
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2016010951A (es) Proteinas de fc multimericas.
MY187047A (en) Selective pyy compounds and uses thereof
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
MX2016010953A (es) Proteinas de fc multimericas.
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
EP3638298A4 (en) PEPTIDIC IMMUNOGENS FROM THE C-TERMINAL END OF A PROTEIN, ALPHA-SYNUCLEIN, AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF SYNUCLEINOPATHIES
MX371033B (es) Productos farmacéuticos mejorados de péptido para resistencia a la insulina.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2013007872A (es) Proteina de fusion anticancer.
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX2020007628A (es) Composiciones y metodos de uso.
PH12017500742A1 (en) Statherin peptides
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.